EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

16th European Multidisciplinary Congress on Urological Cancers (EMUC2024)

 

7-10 November 2024 Lisbon
Close
N. Poster
Poster title
Applicant name
Status
  3-LB TAR-200 /- Cetrelimab and Cetrelimab Alone in Patients With Bacillus Calmette-GuérinUnresponsive High-Risk NonMuscle-Invasive Bladder Cancer: Updated Results From SunRISe-1 Frank DeRosa Received Received
  4-O Differentially expressed miRNA signatures as diagnostic and prognostic molecular biomarkers for seminomatous and non-seminomatous testicular germ cell tumors Panagiotis Vlachostergios Received Received
  6-P Video-Endoscopic Inguinal Lymph Node Dissection (VEILND) has equivalent oncological efficacy and survival to Open Inguinal Lymph Node Dissection (OILND) in penile cancer patients over a 15-year period Ranya Kumar Received Received
  7-P PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform. Margaret Philen Received Received
  9-O Correlation between Fibroblast Activation Protein inhibitor (99mTc-FAPi/SPECT) and histology in patients submitted to retroperitoneal lymph node dissection (RPLND) with residual post-chemotherapy disease in non-seminomatous germ cell tumors (NSGCT) Raul De la Garza Received Received
  9-P A NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy Michael Ladurner Received Received
  10-O Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant but not local disease control in oligorecurrent hormone-sensitive prostate cancer patients: a secondary analysis of the PRECISE-MDT Study Francesco Lanfranchi Received Received
  12-P Extrinsic factors that determine lethal prostate cancer, prostate cancer as the paradigm Brian Miles Received Received
  24-P The Added Value of PSMA PET/CT to MRI for Local Staging in Prostate Cancer Patients Undergoing Radical Prostatectomy Timo Soeterik Received Received
  25-P Imaging and AI supported transformation to better practice - MRI fusion target boost LDR prostate brachytherapy Christof Kastner Received Received
  32-P Does Testosterone Replacement Therapy affect the incidence of prostate cancer? A systematic review Camilla Shidrawi Received Received
  35-P Detection rates of PI-RADS V2.1 for clinically significant prostate cancer and risk stratification of PI-RADS 3 lesions Jonathon Dawson Received Received
  36-P Infectious complications after transrectal vs. transperineal prostate biopsy: a systematic review and meta-analysis Fabian Stangl Received Received
  37-P Geographic variation of Decipher risk score and underlying transcriptomic in patients with post prostatectomy early prostate cancer DANIEL KEIZMAN Received Received
  40-P Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique Charlotte Collins Received Received
  43-P Cost-effectiveness of intraoperative surgical margin assessment during radical prostatectomy Joost van Drumpt Received Received
  45-P Daily adapted prostate re-SBRT with significantly PTV margin reduction and intrafraction drift checking and compensation by means of 1.5T MR-Linac Andrea Gaetano Allegra Received Received
  49-P Real-world outcomes on biochemical recurrence and overall survival following hypofractionated radiotherapy for patients with non- metastatic prostate cancer a single centre experience Bibish Baburaj Received Received
  56-P First clinical application of Comprehensive Motion Management with 1.5T MR-linac on prostate cancer patients treated with radiotherapy: technical issues and suggested workflow Andrea Gaetano Allegra Received Received
  59-P Evaluation of image-guided dose-escalated salvage radiotherapy in patients with macroscopic local recurrences in the prostatectomy bed (SPIDER-SR): A systematic review. Nassim Vibert Received Received
  61-P MRI-directed Ultrasound-guided Transperineal Focal Laser Ablation (TPLA) for Prostate Cancer: one year follow-up of 158 patients Katelijne de Bie Received Received
  62-P Hypofractionated postoperative radiotherapy in prostate cancer: long-term experience Antonio Lazo Received Received
  67-P An interim analysis of the multi center retrospective study PROVIDENCE: Artificial intelligence-based models for estimating the risk of biochemical recurrence with clinical data Anna Nogué Received Received
  71-P The First External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancer in the UK Updating the Nomogram for UK Clinical Practice Ranya Kumar Received Received
  72-P The impact of length and location of positive surgical margins on biochemical recurrence after radical prostatectomy: 5-year follow-up of a nationwide cross-sectional real-world cohort Joost van Drumpt Received Received
  73-P Multicenter validation of a risk classification in patients with expanded active surveillance criteria for unfavorable pathology in prostatectomy specimens Maria Graus Received Received
  86-P Assessing the impact of positive surgical margins on PSA recurrence in NCCN very-high risk prostate cancer patients who underwent Expanded Robotic-assisted Radical Prostatectomy Noriyoshi Miura Received Received
  90-P Ten Year Results of a Phase I Trial of Oncolytic Adenovirus-Mediated Sodium Iodide Symporter (NIS) Gene Delivery in Locally Recurrent Prostate Cancer following Primary Radiotherapy Brian Davis Received Received
  98-P Do patterns of disease characteristics and outcomes differ in prostate cancer from different geographical locations in England? A study from 2 large cancer centres India Reid Received Received
  99-P Effect of the PARP Inhibitor Talazoparib in Combination with Radiation and Enzalutamide in Prostate Cancer Cell Models Miguel Ángel Gómez-Luque Received Received
  102-P First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience Vicki Jardine Received Received
  103-P Assessment of the impact of talazoparib dose reductions on the efficacy of combined talazoparib and enzalutamide treatment in patients with metastatic castrate resistant prostate cancer (mCRPC) in the TALAPRO-2 (TP-2) study Jennifer Browne Received Received
  106-P Higher preoperative maximum Standardized Uptake Values (SUVmax) are associated with a higher risk of metastases following robot-assisted radical prostatectomy for patients undergoing 68Ga-PSMA-11 and 18F-DCFPyL PET/CT Katelijne de Bie Received Received
  117-P Metastatic castration-sensitive prostate cancer treatment patterns by year: a real-world study in Europe Jennifer Browne Received Received
  119-P Androgen Receptor Pathway Inhibitor (ARPI) Monotherapy Use in Metastatic Prostate Cancer (mPC) Patients in the US Anna George Received Received
  120-P Defining the role of radiotherapy in the management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) : a consensus by the Italian Association of Radiotherapy and clinical Oncology (AIRO) Andrea Lancia Received Received
  122-P Therapeutic options in metastatic hormone-sensitive prostate cancer stratified by volume and risk real-world data from a single centre experience Kieran Palmer Received Received
  123-P Exploring the Relationship Between Radiographic Progression-Free Survival and Overall Survival in First-Line Metastatic Castration-Resistant Prostate Cancer Jennifer Browne Received Received
  124-P Apalutamide for metastatic Castration-Sensitive Prostate Cancer: Outcomes in patients with more than 10 bone metastases from the TITAN final analysis Beatriz Garcillan Received Received
  125-P Long-term outcomes of the MEDCARE phase 2 trial: Progression-directed therapy in oligoprogressive castration-resistant prostate cancer Julie den Hartog Received Received
  126-P LIBERTAS, a degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) Alexander Kretschmer Received Received
  130-P Cardiovascular (CV) events and overall survival (OS) in patients (pts) treated with Abiraterone acetate (AA) Vs ENzalutamide (ENZA) for chemotherapy-naïve metastatic castration resistant prostate cancer (mCRPC) in GERmany: AVENGER study Anna George Received Received
  132-P The Randomized, Phase 3 MK-5684-004 Study of CYP11A1 Inhibitor Opevesostat Versus Next-Generation Hormonal Agent (NHA) Switch in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) After 1 Prior NHA Christian Gratzke Received Received
  134-P MK-5684-003: A Randomized, Phase 3 Study of CYP11A1 Inhibitor Opevesostat (MK-5684) Versus Next-Generation Hormonal Agent (NHA) Switch in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) After NHA and Taxane-Based Chemotherapy Evan Yu Yu Received Received
  135-P Big Data Analysis of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer Systemic Treatment Using the PIONEER Platform Pawel Rajwa Received Received
  137-P Phase 1/2 MK-5684-01A Substudy of Oral CYP11A1 Inhibitor Opevesostat (MK-5684) Alone or in Combination With Other Therapies For Metastatic Castration-Resistant Prostate Cancer (mCRPC) Arif Hussain Received Received
  141-P Multiparametric assessment of bone response in metastatic castration resistant prostate cancer patients treated with cabozantinib upon progression to chemotherapy and androgen receptor pathway inhibitors: a phase II study (MERIDIAN) Alberto Dalla Volta Received Received
  148-P Efficacy of Apalutamide in patients with metastatic hormone-sensitive prostate cancer: multicenter study in real-world clinical practice. Raquel Sopeña Sutil Received Received
  149-P Apalutamide and RT of prostate tumor in low-volume, de novo metastatic hormone-sensitive prostate cancer: is there any oncological benefit with combined treatment? Raquel Sopeña Sutil Received Received
  150-P Updated overall survival estimates leveraging long-term extension data from the TITAN study evaluating apalutamide versus placebo in metastatic hormone-sensitive prostate cancer patients Kim Buscemi Received Received
  153-P Treatment patterns and outcomes in elderly patients with castration-resistant prostate cancer (mCRPC): A real-world data analysis Maria Ruiz Vico Received Received
  154-P Lung Nodules in Men with Prior Prostate Cancer (PC): Implications for Diagnosis and Management Cristina Boixareu Received Received
  158-P Prostate cancer education and exercise programme (PEEP): a customised 12 week programme for patients on ADT Uschi Hofmann Received Received
  159-P Impact of metastatic hormone-sensitive prostate cancer (mHSPC) treatments on health-related quality of life (HRQoL): a systematic review (SR) and network meta-analysis (NMA) Tessa van Elst Received Received
  160-P MEMORIAE: a multicenter prospective study evaluating cognitive functioning in patients (pts) with metastatic castration resIstant prostate cancer (mCRPC) treated with abiraterone (ABI) or enzalutamide (ENZA). Fabio Turco Received Received
  162-P Neuropsychiatric symptoms in patients treated with novel hormonal agents in prostate cancer real word experience from a single centre Pedro Frazão Received Received
  166-P Personalized target therapy of locally advanced and metastatic RCC: from retrospective studies to implementation in clinical practice IURII VITRUK Received Received
  171-P Association between tumor KIM-1 gene (HAVCR1) expression and immune infiltrates in renal cell carcinoma Panagiotis Vlachostergios Received Received
  174-P Tivozanib in first-line treatment of metastatic renal cell carcinoma. Experience in our institution. Laura López Received Received
  179-P Lenvatinib plus pembrolizumab (LP) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial Laura Hendrickson Received Received
  184-P Prospective real-world experience with cabozantinib in patients with advanced renal cell carcinoma: interim results of the Belgian REPLICA study Amie Lochrie Received Received
  185-P Understanding radiation exposure during percutaneous cryoablation for T1 renal tumors: a tertiary center analysis. Luna van den Brink Received Received
  188-P Stereotactic MRI-guided adaptive radiotherapy for renal tumors in a solitary kidney Claire van Vliet Received Received
  190-P Stereotactic body radiotherapy for localized kidney cancer, a comparative evaluation with standard surgery within a Young Academic Urologists Working group database Giulio Francolini Received Received
  192-P CaboCombo: interim analyses from an international real-world study assessing the use of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced renal cell carcinoma (aRCC) Ross Katherine Received Received
  195-P Upfront cytoreductive nephrectomy for synchronous metastatic renal cell carcinoma in the era of immunotherapy Iva Nikles Received Received
  198-P Applying TDM and PGx in mRCC patients treated with Sunitinib to customize drug dosing Giorgia Bortolus Received Received
  200-P Retrospective observational study on patients with metastatic renal cell carcinoma treated in first line with Pembrolizumab Axitinib: a Real World project of the Campania Oncology Network Marilena DI Napoli Received Received
  202-P Real-life data on nivolumab as second-line treatment in metastatic kidney cancer Marisa Garrido Onecha Received Received
  208-P Prospective real-world data confirm the tolerability of cabozantinib in patients with advanced renal cell carcinoma: interim results of the Belgian REPLICA study Amie Lochrie Received Received
  211-P Evaluation of the M371 test under real life conditions for the diagnosis of testicular germ cell cancer Carolina DElia Received Received
  212-P Incidence of gonadal and extragonadal germ cell tumours in patients with and without Klinefelters Syndrome Aksh Tailor Received Received
  214-P Circulating Tumor DNA (ctDNA) in Surveillance and Monitoring of Treatment Response in Testis Cancer- A Retrospective Institutional Review Dalia Kaakour Received Received
  216-P Surgical results of robot-assisted post chemotherapy RPLND surgery Anders Kjellman Received Received
  227-P Differences in Immunological Cell Populations Between Peripheral Blood and Tumor Tissue in Patients with NMIBC of Varied Differentiation Grades Eduardo Mariano Albers Received Received
  232-P Unveiling Hidden Threats: Understanding Upper Tract Urothelial Carcinoma in Dutch Renal Transplant Recipients Orlane Figaroa Received Received
  238-P Intravesical treatment in patients with High Risk non-muscle Invasive Bladder Cancer- can treatment with Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C delay or even prevent it? Mohamed Abouelenein Received Received
  243-P VI-RADS followed by Primary Photodynamic Diagnosis (PDD) TURBT versus conventional White-Light TURBT and Re-TURBT in NMIBCs Candidate for Second-Look and Resection: The CUT-less Trial Francesco Del Giudice Received Received
  244-P A phase III, single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease (Orion-BC stud Irene Sormonta Received Received
  247-P Real-world data of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma: experience French Intissar BELRHALI Received Received
  250-P Treatment Patterns in Treatment Naïve High-Risk Non-Muscle Invasive Bladder Cancer across EU4 UK: A Real-World Study Caitlin Ford Received Received
  255-P Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden Kelvin Kwok Received Received
  256-P Characterization of treatment patterns for high-risk non-muscle-invasive bladder cancer in Sweden Kelvin Kwok Received Received
  257-P Cystectomy or conservative treatment in metastatic bladder cancer? IURII VITRUK Received Received
  260-P Real-world data on treatment patterns and guideline adherence in patients with locally advanced and metastatic urothelial bladder cancer (la/mUC) in Germany Markus Kerkmann Received Received
  261-P A Phase 1b-2 study of chemoradiotherapy combined with Nivolumab and Ipilimumab as bladder sparing curative treatment for muscle Invasive bladder cancer: the CRIMI study Marinka Remmelink Received Received
  262-P TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant platinum-based chemotherapy: interim analysis of SunRISe-4 Frank DeRosa Received Received
  263-P Patients with muscle-invasive bladder cancer (MIBC) unfit for radical cystectomy (RC): Trimodal therapy (TMT) Carlos Ayala Received Received
  266-P Impact of histological variants on the response to neoadjuvant chemotherapy in muscle-invasive urothelial bladder cancer Luis Pérez Bartivas Received Received
  267-P Evaluating the Impact of Prophylactic Mesh on Hernia Rates and Surgical Outcomes in Ileal Conduit After Cystectomy: A Systematic Review and Meta-Analysis Tarek Mohamed Received Received
  270-P Real-world experience of neoadjuvant chemotherapy in muscle-invasive bladder cancer at a university center: role of nodal yield and prognostic value of pathological response and nutritional index João Queirós Coelho Received Received
  276-P The added prognostic value of C-Reactive Protein to a clinicopathological prediction model for survival outcomes in patients with muscle invasive bladder cancer in the COBLAnCE cohort. Laura Paper Received Received
  278-P Impact of tumor location on outcomes in high-risk non-muscle-invasive bladder cancer Aleksander &346;lusarczyk Received Received
  282-P Development of new bladder tumor following radical nephroureterectomy for upper tract urothelial carcinoma (UTUC)- a new disease or an old story? Yasmin Abu Ghanem Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
04:23
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

16th European Multidisciplinary Congress on Urological Cancers (EMUC2024)

 

7-10 November 2024 Lisbon
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 07/11/2042 TO 07/11/2042
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert